India commoditised Novo's blockbuster obesity drug. Novo's not flinching
Semaglutide's patent just expired in India. The molecule behind Novo Nordisk's blockbuster obesity drugs, Ozempic and Wegovy, is now fair game for generic manufacturers. An 85 to 90% price drop is expected. Eli Lilly's Mounjaro had already been outselling Wegovy. For most companies, this would be the beginning of an…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Daybreak
See all episodes →UPI is the trojan horse taking small banks into HDFC, Axis's credit-card empire
How India's rich are finding returns in the country's court backlog
Amazon’s quick-commerce win will be less about speed and more about Prime
Similar episodes from other shows
More like Daybreak →
Semaglutide Goes Generic: Big Pharma’s Moat Breaks
Can India break this Pharma Monopoly?
Can India become the pharmacy for weight-loss drugs?
Assam Congress weakens, semaglutide generics, and three dead in Raipur
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.